No Data
No Data
Cybin to Buy Clinical Trial From Entheon Biomedical to Advance Development of CYB004
09:58 AM EDT, 06/07/2022 (MT Newswires) -- Cybin (CYBN) said Tuesday it has agreed to buy a phase 1 study from Entheon Biomedical for $1 million Canadian dollars ($794,450) to boost the clinical devel
BRIEF-Cybin Acquires Dmt Clinical Study From Entheon Biomedical
June 7 (Reuters) - Cybin Inc CYBN.NLB :* CYBIN ACQUIRES DMT CLINICAL STUDY FROM ENTHEON BIOMEDICAL* CYBIN INC- PURCHASE PRICE OF ACQUISITION IS $1,000,000 (CAD)Source text for Eikon: ID:nBw20D4Bma
Cybin Acquires DMT Clinical Study From Entheon Biomedical For C$1M
Cybin Acquires DMT Clinical Study From Entheon Biomedical For C$1M
Entheon Biomedical Announces Non-Brokered Private Placement Financing
Entheon Biomedical Corp. (OTCQB:ENTBF) announced a non-brokered private placement financing for up to 30,000,000 Units at a price of CDN$0.10 per unit, for gross proceeds of up to CDN$3,000,000. Each
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel, New Clinical Research Platform
01:46 PM EDT, 03/29/2022 (MT Newswires) -- Entheon Biomedical Corp. (ENBI.CSE), a biomedical company focused on the research and development of psychedelic drugs and biomarkers to provide personalized
Entheon Biomedical begins enrollment in phase 1 study of DMT for addiction disorders
Entheon Biomedical (OTCQB:ENTBF) said the first patient was enrolled in a phase 1 trial called EBRX-101 evaluating N, N-dimethyltryptamine (DMT) for addiction disorders. In the study — which is being